<DOC>
	<DOCNO>NCT02799082</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety BF-200 ALA ( Ameluz ) use photodynamic therapy ( PDT ) patient suffer actinic keratosis .</brief_summary>
	<brief_title>Evaluation Efficacy Safety BF-200 ALA Used With Photodynamic Therapy Patients With Actinic Keratosis .</brief_title>
	<detailed_description>The treatment comprise one PDT session . If 12 week PDT lesion clear patient enter follow-up period . In case remain lesion completely clear lesion patient receive second PDT day . The final assessment perform 12 week last PDT patient move follow-up phase .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Subjects willing able sign inform consent form . Men woman age 18 85 year inclusive . Subjects general good stable health condition confirm physical examination medical history . Subjects clinically stable medical condition include , limited following disease allow include study , medication take treatment disease match criterion exclude disallowed medication list point 7 , 10 , 11 12 exclusion criterion : control hypertension diabetes mellitus type II hypercholesterolemia osteoarthritis Subjects accept abstain sunbathe solarium study . Subjects least 4 8 clinically confirm actinic keratosis ( AK ) target lesion mild moderate intensity within face bald scalp ( exclude eyelid , lip mucosa ) , i.e . AK grade I II accord Olsen et . al . 1991 . To document confirm diagnosis investigator : Photodocumentation representative lesion evaluate confirmed independent expert . A prestudy biopsy take second representative AK lesion histopathologically evaluate dermatopathological expert . If evaluation photo independent reviewer could confirm diagnosis investigator , biopsy result decide whether subject eligible study . The AK lesion discrete quantifiable ; distance one lesion neighbor lesion great 1.0 cm The diameter AK lesion le 0.5 cm great 1.5 cm . The size baseline AK lesion record measure two large perpendicular diameter . To describe irregular lesion ( ellipsoidal ) investigator measure major minor axis . Both axes minimum 0.5 cm less 1.5 cm . The subject free significant physical abnormality ( e.g. , tattoo , dermatosis ) potential treatment area might cause difficulty examination final evaluation . The subject willing stop use moisturizers topical treatment antiaging product , vitamin A , vitamin C , and/or vitamin E contain ointment cream , green tea preparation study within treatment area . Sunscreens allow , apply treatment area within approximately 24 hour clinical visit lesion count . Women childbearing potential allow participate study , use highly effective method contraception negative serum pregnancy test . Had know hypersensitivity 5aminolevulinic acid ( ALA ) . Were subject immunosuppressive therapy . Suffered porphyria . Showed hypersensitivity porphyrin . Suffered photodermatoses . Had inherit acquire coagulation defect . Had receive medication hypericin systemically act drug phototoxic photoallergic potential psoralens , tetracycline , nalidixic acid , furosemide , amiodarone , phenothiazine , quinolones , fibrates , phytotherapy St. John 's wort , arnica , valerian topically apply phototoxic substance like tar , pitch , psoralens dye like thiazide , methylene blue , toluidine blue , eosine , Bengal rise , acridine within 8 week prior treatment study drug photodynamic therapy ( PDT ) . Had evidence clinically significant , unstable medical condition metastatic tumor tumor high probability metastatic spread cardiovascular ( NYHA class III , IV ) immunosuppressive hematological , hepatic , renal , neurological , endocrine collagenvascular gastrointestinal Had currently malignant benign tumor skin within treatment area ( e.g. , malignant melanoma , basal cell carcinoma , invasive squamous cell carcinoma ) . Used topical treatment treatment area within 12 week PDT treatment BF200 ALA ; biopsy take screen visit allow . Used topical treatment ALA MAL ( methylaminolevulinic acid hydrochloride ) outside treatment area participation study . Systemic treatments one follow within designated period PDT BF200 ALA : Interferon 6 week Immunomodulators immunosuppressive therapy 10 week Cytotoxic drug 6 month Investigational drug 8 week Drugs known major organ toxicity 8 week Corticosteroids ( oral injectable ) 6 week Inhaled corticosteroid ( &gt; 1200 µg/day beclomethasone , &gt; 600 µg/day fluticasone ) 4 week Methylaminolevulinic acid hydrochloride ALA 12 week Known allergy polysorbate 80 , caprylic/capric acid triglyceride , isopropyl alcohol , disodium phosphate dihydrate , sodium hydroxide , hydrochloric acid , propylene glycol ; sodium benzoate . Were know pregnant lactating ( currently within past 3 month ) . Had dermatological disease treatment area surround area could exacerbate treatment topical ALA cause difficulty examination ( e.g . psoriasis , eczema ) . Showed cornu cutaneum like alteration skin face bald scalp ( target area ) . Were currently within past 8 week participate another clinical study . Had active chemical dependency alcoholism assess investigator . Confirmed diagnosis HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>